Niven Ralph's Form 4 filing
Jade Biosciences, Inc. (JBIO) · filed Dec 7, 2023
- Accession no.
- 0001415889-23-015987
- Filed
- Dec 7, 2023
- Trade date
- Dec 5, 2023
- Filing delay
- 2 days
- Rule 10b5-1 plan
- Checked
This filing lists 3 non-derivative transactions and 5 derivative transactions. Open-market sales total $75.0K. It was filed 2 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Niven RalphCIK 0001168060 | Officer (CHIEF SCIENTIFIC OFFICER) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Dec 5, 2023 | Common Stock | MOption exerciseAcquired | +1,400 | $1.74 | +$2,436 | 3,009 | Direct | |
| Dec 5, 2023 | Common Stock | MOption exerciseAcquired | +3,200 | $2.14 | +$6,848 | 6,209 | Direct | |
| Dec 5, 2023 | Common Stock | SSaleDisposed | −4,600 | $16.30F2 | −$74,980 | 1,609 | Direct |
Derivative securities (Table II)
Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.
| Trade date | Security | Transaction | Underlying shares | Unit price | Value | Held after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Dec 5, 2023 | Common Stock | MOption exerciseDisposed | −900 | $0.00 | $0 | 15,108 | Direct | |
| Dec 5, 2023 | Common Stock | MOption exerciseDisposed | −500 | $0.00 | $0 | 10,088 | Direct | |
| Dec 5, 2023 | Common Stock | MOption exerciseDisposed | −500 | $0.00 | $0 | 11,894 | Direct | |
| Dec 5, 2023 | Common Stock | MOption exerciseDisposed | −1,200 | $0.00 | $0 | 37,308 | Direct | |
| Dec 5, 2023 | Common Stock | MOption exerciseDisposed | −1,500 | $0.00 | $0 | 44,732 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F2
The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $16.07 to $16.62, inclusive. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.
Referenced by the price of 1 transaction in Table I.